AIM: To describe cases of acute renal failure (ARF) and of renal failure (RF) from dronedarone retrieved in the general population during post-marketing surveillance through the Italian spontaneous ADR reporting database. METHODS: A case by case analysis was performed. Reports codified with the System Organ Class (SOC) term 'urinary system disorders' of the ADR terminology of the World Health Organization associated with dronedarone treatment were selected. RESULTS: Out of 124,069 ADR reports, in 55 of them dronedarone was listed as the suspected drug. Among these reports, we identified four cases of ARF, two of RF and three cases of increase of blood creatinine submitted by physicians between October 2010 and December 2011. The patient age was from 61 to 84 years and most cases occurred within the first 13 days of initiation of dronedarone therapy (range 6 days-2 months). Only one patient received a co-suspected drug labelled for causing ARF. In all reports but one, positive dechallenge was reported. CONCLUSIONS: Clinicians should be made aware of the risk of ARF/RF associated with dronedarone and of the need to screen patients appropriately for ARF/RF risk factors before starting dronedarone therapy.
AIM: To describe cases of acute renal failure (ARF) and of renal failure (RF) from dronedarone retrieved in the general population during post-marketing surveillance through the Italian spontaneous ADR reporting database. METHODS: A case by case analysis was performed. Reports codified with the System Organ Class (SOC) term 'urinary system disorders' of the ADR terminology of the World Health Organization associated with dronedarone treatment were selected. RESULTS: Out of 124,069 ADR reports, in 55 of them dronedarone was listed as the suspected drug. Among these reports, we identified four cases of ARF, two of RF and three cases of increase of blood creatinine submitted by physicians between October 2010 and December 2011. The patient age was from 61 to 84 years and most cases occurred within the first 13 days of initiation of dronedarone therapy (range 6 days-2 months). Only one patient received a co-suspected drug labelled for causing ARF. In all reports but one, positive dechallenge was reported. CONCLUSIONS: Clinicians should be made aware of the risk of ARF/RF associated with dronedarone and of the need to screen patients appropriately for ARF/RF risk factors before starting dronedarone therapy.
Authors: Samir M Said; Hans D Esperer; Kathrin Kluba; Conrad Genz; Anne K Wiedemann; Hagen Boenigk; Joerg Herold; Alexander Schmeisser; Ruediger C Braun-Dullaeus Journal: Int J Cardiol Date: 2012-04-09 Impact factor: 4.164
Authors: Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Jean-Marc Davy; Martin Herold; Christer Hoglund; Alphons Timmermans; Antonio Alings; David Radzik; Louis Van Kempen Journal: Am Heart J Date: 2008-09 Impact factor: 4.749
Authors: Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez Journal: Clin Med Insights Cardiol Date: 2011-10-06
Authors: Gian Marco Podda; Giovanni Casazza; Francesco Casella; Franca Dipaola; Emanuela Scannella; Ludovica Tagliabue Journal: Int J Gen Med Date: 2012-05-28